Physician profile
Donner Dewdney
NPI 1215964796
$1,899.17
in general payments reported to CMS, 2019-2025
10 companies · $244 in 2025
The $244 reported for 2025 was more than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2020: $225 · 2021: $411 · 2022: $170 · 2023: $322 · 2024: $298 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $863.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $863.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $829.36 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Janssen Pharmaceuticals, INC | $325.06 | 2021-2024 | Spravato, Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $164.15 | 2020-2023 | |
| Otsuka America Pharmaceutical, INC. | $163.94 | 2023-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Allergan, INC. | $143.57 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $105.83 | 2019 | |
| Abbvie INC. | $94.52 | 2021-2024 | Vraylar |
| Vanda Pharmaceuticals INC. | $36.64 | 2024 | Fanapt |
| Lundbeck LLC | $18.26 | 2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $17.84 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donner Dewdney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.